VNRX
VolitionRx Limited
There isn't enough reported data to score VNRX yet.
VNRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
VNRX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
VNRX PE Valuation
VNRX has no meaningful PE right now: it lost money over the past year.
VNRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect VNRX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
VNRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.00 | +$1.81 |
| Q2 2026 | -$3.79 | +$1.27 |
| Q1 2026 | -$4.14 | +$1.24 |
| Q4 2025 | -$4.37 | +$1.83 |
| Q3 2022 | -$11.48 | -$2.48 |
| Q2 2022 | -$11.37 | -$3.17 |
| Q1 2022 | -$10.67 | -$2.07 |
| Q4 2021 | -$10.20 | -$1.20 |
VNRX is still losing money, but far less than before: $3.00 per share over the past year, against $11.48 at its worst in late 2022.
VNRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | +157% |
| Q2 2026 | $398.7K | -2% |
| Q1 2026 | $985.1K | +300% |
| Q4 2025 | $447K | +133% |
| Q3 2025 | $627.3K | +32% |
| Q2 2025 | $406.7K | +2.8% |
| Q1 2025 | $246.4K | +44% |
| Q4 2024 | $191.7K | -21% |
VNRX's revenue is growing: $2M last quarter, up 157% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -207% | +607 points |
| Q2 2026 | -1043% | +506 points |
| Q1 2026 | -543% | +1698 points |
| Q4 2025 | -1078% | +1939 points |
| Q3 2025 | -813% | +424 points |
| Q2 2025 | -1549% | +218 points |
| Q1 2025 | -2241% | +2647 points |
| Q4 2024 | -3017% | +566 points |
VNRX's operating margin was −207% last quarter, up 607 points from the same quarter a year ago, near the top of its range since 2020.
VNRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.6M | -$1M |
| Q2 2026 | -$5.2M | +$1.2M |
| Q1 2026 | -$5.3M | -$989.5K |
| Q4 2025 | -$5.5M | +$1.5K |
| Q3 2025 | -$3.6M | +$1.9M |
| Q2 2025 | -$6.3M | +$431.9K |
| Q1 2025 | -$4.3M | +$4.1M |
| Q4 2024 | -$5.5M | -190% |
VNRX has burned cash in almost every quarter: −$21M over the past year, against −$20M the year before.
VNRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +106% | +9.7M shares |
| 1 year | +249% | +13.5M shares |
| 3 years | +380% | +15M shares |
| 5 years | +611% | +16.2M shares |
| Available history | +865% | +16.9M shares |
VNRX has 19M diluted shares, up 249% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $31,772 |
VNRX Net Leverage
VNRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VNRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 4.8 | Oversold |
VNRX's weekly RSI is 24 (oversold) and its Stochastic is 5 (oversold).
VNRX PE vs Healthcare Sector
VNRX has no meaningful PE right now: it lost money over the past year.
VNRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.20 | 10% below |
| 20 week MA | $0.52 | 65% below |
| 50 week MA | $2.51 | 93% below |
| 100 week MA | $7.06 | 97% below |
| 200 week MA | $14.3 | 99% below |
VNRX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
VNRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.0 | $86.6 | -5.9% |
| 2021 | $86.6 | $64.8 | -25% |
| 2022 | $64.8 | $49.0 | -24% |
| 2023 | $49.0 | $14.3 | -71% |
| 2024 | $14.3 | $12.3 | -14% |
| 2025 | $12.3 | $5.00 | -59% |
| 2026 YTD | $5.00 | $0.18 | -96% |
VNRX has finished every year since 2020 lower, and it's down 96% so far in 2026.